| By Aesica |
| Friday, 25 September 2009 |
 |
Aesica Pharmaceuticals, an innovative and service-driven supplier of APIs, finished dosage
|
|
forms and custom synthesis solutions, announce its licence approval for manufacturing controlled substances.
Aesica's Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs Act 1971.
Granting of this licence followed a programme of investment carried out to enhance the security of the site and its buildings, and the implementation of special procedures for handling of controlled substances.
These changes allow the Aesica Cramlington site to offer facilities for contract manufacture of controlled active pharmaceutical ingredients in |
|
|
quantities from a few kilogrammes in its GMP pilot plant to tonnes in one of its bulk API plants.
The first contract-manufactured controlled drug for one of Aesica’s customers is already in production.
Aesica can now offer such controlled drug manufacturing capability at two sites in the UK:
Queenborough and Cramlington covering both active ingredient synthesis and manufacture and packaging of finished dosage pharmaceutical forms.
Mr. Adam Sims, Commercial Director of Aesica, said: “This is a significant step forward for Aesica in terms of broadening our capabilities in line with our customers’ demand.”
To learn more please visit Aesica at CPhI in Madrid
October 13th - 15th 2009
Stand No. 4B29 (Hall 4)
Feria de Madrid.
Or please contact us directly: |
|
Europe:
Maria Koustareva
Marketing Manager
Tel: +44 (0)191 218 1969
maria.koustareva@aesica-pharma.com
USA:
Michael Staff
VP, Business Development
Tel: +1 201.960.1828
michael.staff@aesica-pharma.com
Website:
http://www.aesica-pharma.com
Want to read more?
Aesica Pharmaceutical Services Corporate Website
Aesica Pharmaceuticals - supplier of APIs, Formulations and Custom Synthesis Solutions
Aesica Acquires Third Major Manufacturing Facility
Aesica establishes US subsidiary to drive further growth in North America
|
|
|
